1.5.2 Corticosteroids

Budesonide
  • Budenofalk® capsules containing e/c granules 3mg (£63.04 = 9mg daily)
  • Entocort CR® capsules containing e/c m/r granules 3mg (£63.04 = 9mg once daily)
  • Rectal foam, one metered application contains 2mg budesonide (£57.11 = 14 application canister)
  • Orodispersible tablets 1mg

Indications and dose

  • Budenofalk® capsules and Entocort CR® 3mg capsules are included for induction of remission in mild or moderate ileocaecal Crohn's disease.
    • Budenofalk®: 9mg (three capsules) once daily or 3mg three times daily, for up to 8 weeks; reduce dose for the last 2 weeks of treatment
    • Entocort CR®: 9mg (three capsules) once daily in the morning for up to 8 weeks; reduce dose for the last 2–4 weeks of treatment
  • Rectal foam is included for active Ulcerative colitis affecting the sigmoid colon and rectum
    • One metered application once daily for up to 8 weeks
  • Orodispersible tablets (hospital only) are included for induction of remission in eosinophilic oesophagitis in line with NICE TA708 (see notes below)

Notes

  1. Prescribe capsules by brand (to prevent confusion where multiple brands contain similar ingredients)
  2. Treatment with budesonide orodispersible tablets should be initiated by a physician with experience in the diagnosis and treatment of eosinophilic oesophagitis (Summary of Product Characteristics)
  3. NICE TA708: Budesonide as an orodispersible tablet is recommended as an option for inducing remission of eosinophilic oesophagitis (June 2021)
Prednisolone
  • Retention enema 20mg in 100ml (£7.50 = 7 enemas)
  • Suppositories 5mg (£55.47 = 10 suppositories)
Budesonide prolonged release (Cortiment®)

The routine commissioning of budesonide 9mg prolonged release multi-matrix tablets used for up to 8 weeks treatment is not accepted in Devon for induction of remission in adults with mild to moderate active ulcerative colitis where 5-aminosalicylic acid (5-ASA) treatment is not sufficient (see Commissioning Policy for more details). The policy indicates that in exceptional circumstances the Trust-Managed Individual Patient Treatments process can be used for this indication.

Corticosteroids in Inflammatory Bowel Disease (IBD)

  1. Before starting steroids consider carefully if symptoms are due to active disease or other diagnosis e.g. co-existing irritable bowel syndrome. A raised CRP may help to confirm active disease.
  2. Avoid ultra-short or low doses. For the majority of patients start at prednisolone 40mg and decrease over 8 weeks.
  3. Steroids have no role in maintenance therapy.
  4. At one year, approximately 50% of patients with ulcerative colitis will be steroid dependent or steroid refractory.

Decision to start immunomodulator therapy for patients with ulcerative colitis will be made by gastroenterologist, typically if:

  • More than 1 course of steroids in any 2 year period
  • Following any severe attack requiring IV steroids

 

Home > Formulary > Chapters > 1. Gastrointestinal > 1.5 Chronic bowel disorders > 1.5.2 Corticosteroids

 

  • First line
  • Second line
  • Specialist
  • Hospital